Isomorphic Labs 融资 50 亿美元,推进候选药物进入临床试验

2021年从Google旗下DeepMind分拆出来的AI药物发现平台Isomorphic Labs在C轮融资中筹集了50亿美元,用于推动其候选药物进入临床试验。
本轮融资由Greenoaks和Sequoia Capital联合领投,新投资方Andreessen Horowitz及其他投资者也参与其中。公司现有全部投资方同样跟投,包括Alphabet旗下的风投部门GV和Capital G,以及Thrive Capital、MGX、淡马锡和英国主权AI基金。
Isomorphic Labs打造了一套AI药物设计引擎,使用一系列仿真AI模型探索化学的各个领域,以帮助公司设计药物。该公司的研究建立在DeepMind突破性的蛋白质折叠AI模型AlphaFold之上,公司称其项目已在肿瘤学和免疫学领域取得“积极的临床前结果”。该实验室已与Eli Lilly、Novartis和Johnson & Johnson等制药巨头达成合作。
这笔新资金紧随5月份21亿美元的B轮融资之后到位,将用于继续开发其药物设计引擎,并拓展至更多类型的药物领域。
这是Isomorphic自其创始人兼CEO Demis Hassabis卸任DeepMind负责人、专注药物发现以来的首轮融资;Hassabis同时转任DeepMind董事长。Hassabis与时任DeepMind总监John Jumper因该实验室在AlphaFold上的工作共同获得诺贝尔化学奖——AlphaFold是一套仅凭基因序列即可预测蛋白质三维结构的系统。
Isomorphic未披露其最新估值。Bloomberg本月早些时候报道称,该实验室正寻求以500亿美元估值融资。
生物科技与健康领域最新动态
译文由英文原文机器翻译,术语按行业惯例统一,可在文末展开原文核对。
查看英文原文(Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials)
Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.
The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.
Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.
The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.
The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.
Isomorphic did not disclose its new valuation. Bloomberg reported earlier this month that the lab was looking to raise funding at a $50 billion valuation.
Latest in Biotech & Health
原文为英文,正文由自动抓取并保留原文。
原文发布于 TechCrunch AI(Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials),标题、摘要与正文由机器翻译,术语按行业惯例统一,未经人工逐句校订。